NeuroBo Pharmaceuticals, Inc. (NRBO)

NASDAQ: NRBO · IEX Real-Time Price · USD
+0.012 (2.94%)
At close: Nov 28, 2023, 1:25 PM
+0.005 (1.20%)
After-hours: Nov 28, 2023, 5:37 PM EST

Company Description

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases.

It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity.

The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001.

NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

NeuroBo Pharmaceuticals, Inc.
NeuroBo Pharmaceuticals logo
Country United States
Industry Biotechnology
Sector Healthcare
Employees 2
CEO Hyung-Heon Kim

Contact Details

545 Concord Avenue, Suite 210
Cambridge, Massachusetts 02138
United States
Phone (857) 702-9600

Stock Details

Ticker Symbol NRBO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001638287
CUSIP Number 64132R107
ISIN Number US64132R2067
Employer ID 47-2389984
SIC Code 2834

Key Executives

Name Position
Dr. Ben Gil Price M.D. Chief Executive Officer and Pres
Dr. Matthew Bardin BCPS, Pharm.D. Senior Vice President of Operations
Frank Kondrad Vice President of Corporate and Business Development

Latest SEC Filings

Date Type Title
Nov 13, 2023 10-Q Quarterly Report
Nov 13, 2023 8-K Current Report
Nov 6, 2023 8-K Current Report
Oct 30, 2023 8-K Current Report
Sep 22, 2023 8-K Current Report
Sep 19, 2023 8-K Current Report
Sep 15, 2023 8-K Current Report
Aug 24, 2023 8-K Current Report
Aug 14, 2023 8-K Current Report
Aug 9, 2023 10-Q Quarterly Report